Figure 2.

Prostate and NSCL human carcinoma cells exposed to vorinostat or entinostat are more sensitive to avelumab-mediated ADCC. DU145 (A, C) and PC-3 (B, D) prostate carcinoma cells and H460 (E, G) and H441 (F, H) NSCL carcinoma cells were exposed to vorinostat (A, B, E, F), entinostat (C, D, G, H), or DMSO, as described in Materials and Methods, prior to being used as targets for NK cell lysis (4 h), in the presence or absence of avelumab or isotype control (2 ng/mL). Purified NK cells from 2 healthy donors were used as effectors at an effector:target ratio of 30:1. Results are presented as mean ± S.E.M. from 3 replicate wells, and are representative of 2–4 independent experiments. Asterisks denote statistical significance relative to controls (2-way ANOVA). * p < 0.05; ** p < 0.01; *** p < 0.001.